WARRINGTON, Pa., July 29, 2011 (GLOBE NEWSWIRE) -- Discovery Laboratories, Inc. (Nasdaq:DSCO), a specialty biotechnology company dedicated to improving the standard of respiratory critical care through its KL4 surfactant and aerosolized drug delivery technology platform, today announced its intent to seek regulatory approval to market AFECTAIR, a potential new product offering. AFECTAIR originates from the AEROSURF® development program and is a proprietary disposable patient interface adapter that simplifies the delivery of any aerosolized medication to critical-care patients requiring ventilatory support from either intermittent mechanical ventilation or continuous positive airway pressure. According to national health statistics and market assessment data recently obtained from an independent consulting firm, it is estimated that more than 1.3 million patients annually in the United States and European Union receive aerosolized medications while requiring ventilator support. Discovery Labs will host a conference call today at 10:00 AM EDT to introduce AFECTAIR and provide additional insight into the utility and commercial potential of this technology. Conference call details are below.
